For research use only. Not for therapeutic Use.
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis[1][2][3][4].
Lysophosphatidylcholine (3-100 μM, 24 h) reduced HUVEC viability[1].
Lysophosphatidylcholines (12.5μM, 4 h) upregulates gene expression of IL-1β in human peripheral blood monocytes[2].
Lysophosphatidylcholines (75μM, 24 h) induces apoptosis in HUVEC through a p38-mitogen-activated protein kinase-dependent mechanism[3].
Lysophosphatidylcholines (0.1-20 mg/kg, Oral, single dose) protects against sepsis-induced lethality on albino ICR mice[4].
Lysophosphatidylcholines (0.1-20 mg/kg, Oral, single dose) enhances bacterial clearance, blocks cecal ligation and puncture (CLP)-induced neutrophil deactivation and increases bactericidal activity of neutrophils[4].
| Catalog Number | R067984 |
| CAS Number | 9008-30-4 |
| Purity | ≥95% |
| Reference | [1]. Kim E A, et al. Lysophosphatidylcholine induces endothelial cell injury by nitric oxide production through oxidative stress [J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2009, 22(4): 325-331. [2]. Liu-Wu Y, et al. Lysophosphatidylcholine induces the production of IL-1β by human monocytes [J]. Atherosclerosis, 1998, 137(2): 351-357. [3]. Takahashi M, et al. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism [J]. Atherosclerosis, 2002, 161(2): 387-394. [4]. Yan J J, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis [J]. Nature medicine, 2004, 10(2): 161-167. |
